Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis Canadian Erythropoietin Study Group
Members of the Canadian Erythropoietin Study Group are given at the end of this paper.
Correspondence and requests for reprints to: Dr Andreas Laupacis, Robarts Research Institute, PO Box 5015, London, Ontario N6A 5KB, Canada. BrMed3 1990;300:573-8
BMJ
VOLUME 300
Abstract Objective-To determine whether recombinant human erythropoietin improves the quality of life and exercise capacity of anaemic patients receiving haemodialysis. Design-A double blind, randomised, placebo controlled study. Setting-Eight Canadian university haemodialysis centres. Patients-118 Patients receiving haemodialysis aged 18-75 with haemoglobin concentrations
Members of the Canadian Erythropoietin Study Group are given at the end of this paper.
Correspondence and requests for reprints to: Dr Andreas Laupacis, Robarts Research Institute, PO Box 5015, London, Ontario N6A 5KB, Canada. BrMed3 1990;300:573-8
BMJ
VOLUME 300
Abstract Objective-To determine whether recombinant human erythropoietin improves the quality of life and exercise capacity of anaemic patients receiving haemodialysis. Design-A double blind, randomised, placebo controlled study. Setting-Eight Canadian university haemodialysis centres. Patients-118 Patients receiving haemodialysis aged 18-75 with haemoglobin concentrations
